No abstract

No abstract

Objective: Drug Evaluation & Approval System Reforming (EASR) is a major initiative of the State Council’s “Delegate power and optimize service” and “random inspection and information disclosure” policies in the R&D of pharmaceutical industry. The research aims to analyze the impact of drug EASR on the Chinese pharmaceutical organizational structure since 2015. Methods: Based on the relationship analysis between EASR and the organization structure of the government and pharmaceutical industry, this paper uses the Panel Data model to analyze the relevant factors affecting the R&D organizational structure. Results and Conclusion: The results show that it is significantly and positively correlated between the clinical trial behavior and the technology incubator, the domestic technology transfer and the technology macro environment. The organizational structure optimization path of the pharmaceutical industry based on the EASR includes the specialized division, big data model, international cooperation, MAH and technology finance model.

The aim of Chinese pharmaceutical industry restructuring and upgrading is to achieve the transformation from incremental expansion to the stock adjustment road. As the mail strength of industrial restructuring, pharmaceutical companies of state-owned and state-holding are the main object of pharmaceuticals industry mixed ownership reforms. Basing on the analyzing of mixed ownership reforming process and industry restructuring, the paper discussed the impacting factors of Chinese pharmaceutical restructuring with the empirical analysis of Panel Data model. Result display that the state-owned companies perform the more quantity, extensive mode of production, which need the stock adjustment model. Restructuring road include the incremental and stock adjusting, micro-stock adjusting, social capital participating and state-owned capital exchange building.

It is necessary to play a leading and exemplary role in the implementation of Chinese innovative development strategy, because of the economic, social and political status of state-owned pharmaceutical enterprises. Based on describing pharmaceutical ownership reforming and innovation status, the paper analyzed the dynamic innovation performance of the State-owned pharmaceutical enterprises by the Malmquist index of DEA (Data Envelopment Analysis), and result shows that the biological product field of state-owned enterprises obtained better innovation performance. Then the paper discussed the innovation performance of state-owned pharmaceutical enterprises by the empirical analysis of Panel data model, the results showed that the state-owned enterprise have the serious status of R&D resource concentrating and excessing, but it is still achieve major force of Chinese pharmaceutical economic growth based on innovative activities. At last, the paper offered the upgrading road of state-owned enterprises innovation capability, such as the market radiating and integrating, micro-cooperation, organizational restructuring, and cross-regional integration.